AR040792A1 - Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas - Google Patents
Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicasInfo
- Publication number
- AR040792A1 AR040792A1 AR20030102806A ARP030102806A AR040792A1 AR 040792 A1 AR040792 A1 AR 040792A1 AR 20030102806 A AR20030102806 A AR 20030102806A AR P030102806 A ARP030102806 A AR P030102806A AR 040792 A1 AR040792 A1 AR 040792A1
- Authority
- AR
- Argentina
- Prior art keywords
- erb
- antineoplasic
- therapies
- therapeutic combinations
- administration
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000000118 anti-neoplastic effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 229940034982 antineoplastic agent Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 230000005865 ionizing radiation Effects 0.000 abstract 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 abstract 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 229940009456 adriamycin Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960004117 capecitabine Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 238000011285 therapeutic regimen Methods 0.000 abstract 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 abstract 1
- 229960000303 topotecan Drugs 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40170502P | 2002-08-07 | 2002-08-07 | |
| US46224703P | 2003-04-11 | 2003-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040792A1 true AR040792A1 (es) | 2005-04-20 |
Family
ID=31720553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102806A AR040792A1 (es) | 2002-08-07 | 2003-08-05 | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040067942A1 (enExample) |
| EP (1) | EP1549320A1 (enExample) |
| JP (1) | JP2005538129A (enExample) |
| CN (1) | CN1674908A (enExample) |
| AR (1) | AR040792A1 (enExample) |
| AU (1) | AU2003249450A1 (enExample) |
| BR (1) | BR0313470A (enExample) |
| CA (1) | CA2494270A1 (enExample) |
| IL (1) | IL166423A0 (enExample) |
| MX (1) | MXPA05001430A (enExample) |
| NO (1) | NO20051170L (enExample) |
| PA (1) | PA8578001A1 (enExample) |
| PE (1) | PE20040990A1 (enExample) |
| PL (1) | PL375414A1 (enExample) |
| RU (1) | RU2005102836A (enExample) |
| TW (1) | TW200404532A (enExample) |
| WO (1) | WO2004014386A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| US7695731B2 (en) | 2004-03-22 | 2010-04-13 | Cordis Corporation | Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury |
| JP4823894B2 (ja) | 2004-04-09 | 2011-11-24 | 中外製薬株式会社 | 新規水溶性プロドラッグ |
| ME01267B (me) | 2004-05-06 | 2013-06-20 | Warner Lambert Co | 4-fenilaminokinazolin-6-ilamidi |
| WO2005117887A1 (en) * | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with gemcitabine and an egfr-inhibitor |
| CN1968706A (zh) | 2004-06-03 | 2007-05-23 | 霍夫曼-拉罗奇有限公司 | 用顺铂和egfr－抑制剂治疗 |
| EP1761264A1 (en) * | 2004-06-03 | 2007-03-14 | F.Hoffmann-La Roche Ag | Treatment with irinotecan (cpt-11) and an egfr-inhibitor |
| CA2569139A1 (en) * | 2004-06-04 | 2005-12-22 | Smithkline Beecham (Cork) Limited | Lapatinib with letrozole for use in a treatment of breast cancer |
| TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| JP2009538317A (ja) * | 2006-05-26 | 2009-11-05 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ |
| RU2325199C2 (ru) * | 2006-06-20 | 2008-05-27 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ комбинированного лечения местно-распространенных форм рака шейки матки |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| KR20100102609A (ko) * | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법 |
| JP2014514359A (ja) * | 2011-05-06 | 2014-06-19 | メリマック ファーマシューティカルズ インコーポレーティッド | 抗ＥｒｂＢ３剤を含む併用治療において有毒な薬物相互作用を予防するための方法 |
| WO2021178789A1 (en) * | 2020-03-06 | 2021-09-10 | Deciphera Pharmaceuticals, Llc | Methods of using rebastinib in the treatment of different cancerous disorders |
| CN118576601A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合产品在制备用于治疗结肠癌的药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287223B1 (en) * | 1997-04-11 | 2001-09-11 | Liechty, Ii Victor Jay | Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position |
| US6147107A (en) * | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
| US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| RU2292904C2 (ru) * | 2001-01-09 | 2007-02-10 | Мерк Патент Гмбх | Комбинированная терапия, использующая ингибиторы рецептора тирозинкиназы и ингибиторы ангиогенезиса |
-
2003
- 2003-07-22 PA PA20038578001A patent/PA8578001A1/es unknown
- 2003-07-28 IL IL16642303A patent/IL166423A0/xx unknown
- 2003-07-28 WO PCT/IB2003/003388 patent/WO2004014386A1/en not_active Ceased
- 2003-07-28 CN CNA038191180A patent/CN1674908A/zh active Pending
- 2003-07-28 EP EP03784371A patent/EP1549320A1/en not_active Withdrawn
- 2003-07-28 RU RU2005102836/14A patent/RU2005102836A/ru not_active Application Discontinuation
- 2003-07-28 JP JP2004527183A patent/JP2005538129A/ja not_active Withdrawn
- 2003-07-28 BR BR0313470-9A patent/BR0313470A/pt not_active IP Right Cessation
- 2003-07-28 AU AU2003249450A patent/AU2003249450A1/en not_active Abandoned
- 2003-07-28 CA CA002494270A patent/CA2494270A1/en not_active Abandoned
- 2003-07-28 PL PL03375414A patent/PL375414A1/xx not_active Application Discontinuation
- 2003-07-28 MX MXPA05001430A patent/MXPA05001430A/es unknown
- 2003-08-01 US US10/632,281 patent/US20040067942A1/en not_active Abandoned
- 2003-08-04 PE PE2003000768A patent/PE20040990A1/es not_active Application Discontinuation
- 2003-08-05 AR AR20030102806A patent/AR040792A1/es unknown
- 2003-08-06 TW TW092121515A patent/TW200404532A/zh unknown
-
2005
- 2005-03-04 NO NO20051170A patent/NO20051170L/no unknown
-
2006
- 2006-08-14 US US11/464,249 patent/US20060293323A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05001430A (es) | 2005-06-06 |
| NO20051170L (no) | 2005-05-06 |
| IL166423A0 (en) | 2006-01-15 |
| PE20040990A1 (es) | 2004-12-27 |
| PL375414A1 (en) | 2005-11-28 |
| BR0313470A (pt) | 2005-06-21 |
| CN1674908A (zh) | 2005-09-28 |
| JP2005538129A (ja) | 2005-12-15 |
| PA8578001A1 (es) | 2004-05-07 |
| CA2494270A1 (en) | 2004-02-19 |
| AU2003249450A1 (en) | 2004-02-25 |
| EP1549320A1 (en) | 2005-07-06 |
| TW200404532A (en) | 2004-04-01 |
| US20040067942A1 (en) | 2004-04-08 |
| WO2004014386A1 (en) | 2004-02-19 |
| RU2005102836A (ru) | 2005-08-10 |
| US20060293323A1 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040792A1 (es) | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas | |
| EP4389225A3 (en) | Cancer treatments using combinations of type 2 mek and erk inhibitors | |
| WO2015184145A8 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| EP4512480A3 (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| MX2022001075A (es) | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). | |
| NO20072055L (no) | Fremgangsmater og sammensetninger for behandling av flaviviruser, pestiviruser og hepacivirus | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| PT1307197E (pt) | Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida | |
| AR062658A1 (es) | Terapias de combinacion para artritis reumatoide | |
| AR054371A1 (es) | Metodos y composiciones para manejo de desordenes psicoticos | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| MX2009012155A (es) | Combinación farmacéutica sinérgica para el tratamiento de cáncer. | |
| WO2015095838A3 (en) | Cancer treatments using combinations of mek type i and erk inhibitors | |
| JP2016515586A5 (enExample) | ||
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| WO2015142867A1 (en) | Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells | |
| MX2024004213A (es) | Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| RU2008148597A (ru) | Фармацевтические комбинации | |
| PH12022551371A1 (en) | Macrocycles for use in treating disease | |
| MX2022006500A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
| CO5160295A1 (es) | Nuevas combinaciones farmaceuticas para inhibidores de la nos cionalmente un ssri | |
| MX2022013757A (es) | Metodos para el tratamiento del cancer con una combinacion de un antagonista de la pd-1, una quimioterapia con terapia de radiacion, y un inhibidor de parp. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |